68Ga-MY6349 PET/CT in Solid Tumors
NCT07046702 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-07-15
Summary
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
Conditions
- Solid Tumor
- Trop2
- PET/CT
Interventions
- DIAGNOSTIC_TEST
-
68Ga-MY6349
Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
Sponsors & Collaborators
-
The First Affiliated Hospital of Xiamen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-10
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
NCT05814835 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors
NCT06203574 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours
NCT06770478 ·Status: RECRUITING ·Phase: NA
-
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
NCT04499365 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
NCT05930457 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of FDG and FAPI in Patients With Various Types of Cancer
NCT04416165 ·Status: RECRUITING ·Phase: NA
-
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
NCT04588064 ·Status: COMPLETED ·Phase: NA
-
68Ga-NI-FAPI PET/CT: First-in-human Study
NCT06688305 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
NCT06084767 ·Status: RECRUITING ·Phase: NA
-
CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors
NCT06720298 ·Status: NOT_YET_RECRUITING
-
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
NCT05346276 ·Status: COMPLETED
-
First Human Trial of Targeting MDM2/MDMX PET Imaging
NCT06443762 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG
NCT05543317 ·Status: COMPLETED ·Phase: NA
-
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor
NCT06126705 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
NCT06597539 ·Status: RECRUITING
-
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
NCT05000372 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
68Ga-JH04 PET/CT in Patients With Various Types of Cancer
NCT06455735 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
NCT06644274 ·Status: RECRUITING
-
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT06646952 ·Status: RECRUITING
-
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT07144085 ·Status: RECRUITING ·Phase: PHASE1
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 ·Status: RECRUITING
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
NCT06455761 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
NCT06740240 ·Status: RECRUITING ·Phase: EARLY_PHASE1